Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Langenau – page 33

649 clinical trials in Langenau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Langenau at a glance
649
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

649 trials in Langenau

Open in trial search

Testosterone deficiency syndrome+2

Not recruiting

Bioavailability, Safety and Tolerability of elinzanetant (BAY 3427080) in Healthy Adults for Treatment of Vasomotor Symptoms

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nemtabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Hormone-dependent prostate cancer+1

Not recruiting

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:BioNTech SE

Dementia Alzheimer's type

Not recruiting

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK4527226
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Major depression

Not recruiting

Study of lavender oil (Silexan) in patients with mild to moderate major depressive disorder comparing its effectiveness to placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lavender Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colitis ulcerative

Not recruiting

Study of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Colitis ulcerative

Not recruiting

Study of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Langenau

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical research focusing on plaque psoriasis and psoriatic arthritis, evaluating novel therapeutic approaches for both biologic-naive and experienced patients. Studies aim to assess treatment efficacy in reducing disease symptoms and improving patient outcomes.

  • Moderate to Severe Plaque Psoriasis
  • Active Psoriatic Arthritis
  • Long-term Safety Studies

Multiple investigations are comparing new therapeutic agents against placebo and established treatments.

02 Chronic Skin Disorders

Comprehensive studies addressing hidradenitis suppurativa and atopic dermatitis. Research focuses on evaluating new treatments for these challenging conditions, with emphasis on both immediate efficacy and long-term management.

  • Hidradenitis Suppurativa Management
  • Atopic Dermatitis Treatments
  • Novel Therapeutic Approaches

Trials are examining both topical and systemic treatments for optimal disease control.

03 Dermatological Conditions

Innovative research addressing various skin conditions including chronic venous ulcers, actinic keratosis, and rosacea. Studies range from stem cell therapies for wound healing to novel topical treatments.

  • Wound Healing Therapies
  • Skin Lesion Treatments
  • Inflammatory Conditions

Research includes both traditional and cutting-edge therapeutic approaches.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.